Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 2:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 44 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Mirikizumab Clear all
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of Mirikizumab Solution (LY3074828) in Healthy Participants

NCT07446101
View directory record Official record
Conditions
Healthy
Interventions
Mirikizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
5
States / cities
Daytona Beach, Florida • Dilworth, Minnesota • Dallas, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 10, 2026, 2:46 AM EDT
Terminated Phase 3 Interventional Results available

A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)

NCT03556202
View directory record Official record
Conditions
Psoriasis
Interventions
Mirikizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,936 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
47
States / cities
Birmingham, Alabama • Beverly Hills, California • Encinitas, California + 41 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2023 · Synced Sep 10, 2026, 2:46 AM EDT
Active, not recruiting No phase listed Observational

VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Study

NCT06249555
View directory record Official record
Conditions
Crohn's Disease
Interventions
Vedolizumab (VDZ), Ustekinumab (UST), Risankizumab (RISA), Guselkumab (GUS), Mirikizumab (MIR)
Drug
Lead sponsor
Alimentiv Inc.
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
11
States / cities
Sun City, Arizona • Evanston, Illinois • Iowa City, Iowa + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 10, 2026, 2:46 AM EDT
Completed Phase 2 Interventional Results available

A Study of Mirikizumab (LY3074828) in Children and Teenagers With Ulcerative Colitis (UC)

NCT04004611
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Mirikizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
2 Years to 17 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
22
States / cities
Orange, California • San Francisco, California • Denver, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2024 · Synced Sep 10, 2026, 2:46 AM EDT
Recruiting Phase 2 Interventional

LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:

NCT07186101
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
LY4268989, Mirikizumab, LY4268989 Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
40
States / cities
Scottsdale, Arizona • Anaheim, California • Lancaster, California + 36 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 10, 2026, 2:46 AM EDT
Not yet recruiting Phase 4 Interventional

Evaluating the Efficacy and Safety of Mirikizumab in Adults Over 60 With Moderate to Severe Crohn's Disease and Ulcerative Colitis

NCT07059130
View directory record Official record
Conditions
Crohn Disease (CD), Crohns Disease, Ulcerative Colitis (UC)
Interventions
Mirikizumab
Biological
Lead sponsor
Rubix LS
Industry
Eligibility
60 Years to 99 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Lawrence, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 9, 2025 · Synced Sep 10, 2026, 2:46 AM EDT
Recruiting No phase listed Observational

COMPARE - Pediatric Inflammatory Bowel Disease (PIBD)

NCT07198113
View directory record Official record
Conditions
Ulcerative Colitis, Pediatric, Inflammatory Bowel Diseases, Crohn Disease
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
1 Year to 18 Years
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
4
States / cities
Chapel Hill, North Carolina • Charlotte, North Carolina • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 10, 2026, 2:46 AM EDT
Recruiting Phase 2 Interventional

A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease

NCT07483073
View directory record Official record
Conditions
Colitis, Ulcerative, Crohn Disease
Interventions
Mirikizumab - Intravenous (IV), Mirikizumab - Subcutaneous (SC), LY4395089
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
14
States / cities
Scottsdale, Arizona • Los Angeles, California • Oxnard, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 10, 2026, 2:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Bioequivalence Study of Mirikizumab (LY3074828) Solution in Healthy Participants

NCT05644353
View directory record Official record
Conditions
Healthy
Interventions
Mirikizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
6
States / cities
Cypress, California • Daytona Beach, Florida • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Sep 10, 2026, 2:46 AM EDT
Recruiting Phase 4 Interventional

Mirikizumab in the Treatment of Chronic Inflammatory Conditions of the Pouch

NCT06864403
View directory record Official record
Conditions
Pouchitis, Pouches, Ileoanal, Pouch, Ileal
Interventions
Mirikizumab - Intravenous (IV), Mirikizumab - Subcutaneous (SC)
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
Los Angeles, California • Rochester, Minnesota • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Sep 10, 2026, 2:46 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

NCT04232553
View directory record Official record
Conditions
Crohn's Disease
Interventions
Mirikizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
996 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
54
States / cities
Dothan, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 10, 2026, 2:46 AM EDT
Completed Phase 1 Interventional Results available

A Study of Mirikizumab in Participants With Plaque Psoriasis

NCT03718884
View directory record Official record
Conditions
Psoriasis
Interventions
Drug Cocktail, Mirikizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Anaheim, California • DeLand, Florida • High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 28, 2024 · Synced Sep 10, 2026, 2:46 AM EDT
Recruiting Phase 4 Interventional

A Study to Measure Mirikizumab Levels in Breast Milk of Lactating Participants Receiving Mirikizumab Therapeutically for an Approved Indication

NCT07612267
View directory record Official record
Conditions
Lactation, Inflammatory Bowel Disease
Interventions
Mirikizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
3 Weeks and older · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
5
States / cities
Glenview, Illinois • Iowa City, Iowa • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 10, 2026, 2:46 AM EDT
Completed Phase 3 Interventional Results available

An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

NCT03518086
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Mirikizumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,281 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
98
States / cities
Dothan, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 83 more
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced Sep 10, 2026, 2:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Compare Two Formulations of Mirikizumab (LY3074828) in Healthy Participants

NCT05069896
View directory record Official record
Conditions
Healthy
Interventions
Mirikizumab Prefilled Syringe, Mirikizumab Autoinjector
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
237 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
3
States / cities
Daytona Beach, Florida • Springfield, Missouri • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Sep 10, 2026, 2:46 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

NCT03519945
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Mirikizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,058 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
48
States / cities
Dothan, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 10, 2026, 2:46 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque Psoriasis

NCT03482011
View directory record Official record
Conditions
Psoriasis
Interventions
Mirikizumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
10
States / cities
Farmington, Connecticut • Coral Gables, Florida • Ocala, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2020 · Synced Sep 10, 2026, 2:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Injections of LY3074828 in Healthy Participants

NCT03886948
View directory record Official record
Conditions
Healthy
Interventions
LY3074828, Pre-filled syringe (PFS), Autoinjector (AI)
Drug · Device
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Feb 19, 2024 · Synced Sep 10, 2026, 2:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Bioequivalence Study of Citrate Free Mirikizumab (LY3074828) in Healthy Participants

NCT06475729
View directory record Official record
Conditions
Healthy
Interventions
Citrate-Free Mirikizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
498 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
6
States / cities
Anaheim, California • Daytona Beach, Florida • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Sep 10, 2026, 2:46 AM EDT
Completed Phase 3 Interventional Results available

A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

NCT03524092
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Mirikizumab SC, Mirikizumab IV, Placebo SC
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
57
States / cities
Dothan, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 10, 2026, 2:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Two Different Formulations of LY3074828 in Healthy Participants

NCT03188510
View directory record Official record
Conditions
Healthy
Interventions
LY3074828
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 24, 2024 · Synced Sep 10, 2026, 2:46 AM EDT
Not yet recruiting Phase 4 Interventional

MIRICURE: Mirikizumab With Curettage and Repair (Closure) for Perianal Fistulizing Crohn's Disease

NCT07782021
View directory record Official record
Conditions
Crohn's Disease, Perianal Fistula
Interventions
Mirikizumab, Fistula Tract Curettage and Closure
Drug · Procedure
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Louis, Missouri • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 10, 2026, 2:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Bioequivalence Study of Mirikizumab (LY3074828) in Healthy Participants

NCT05515601
View directory record Official record
Conditions
Healthy
Interventions
Mirikizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
396 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
6
States / cities
Cypress, California • Daytona Beach, Florida • Dilworth, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2024 · Synced Sep 10, 2026, 2:46 AM EDT
Completed Phase 2 Interventional Results available

A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Plaque Psoriasis

NCT02899988
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Mirikizumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
12
States / cities
Ocala, Florida • Tampa, Florida • Plainfield, Indiana + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2020 · Synced Sep 10, 2026, 2:46 AM EDT